Candel Therapeutics, Inc. (CADL): Price and Financial Metrics

Candel Therapeutics, Inc. (CADL): $1.58

0.04 (+2.60%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

F

Add CADL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#262 of 362

in industry

CADL Price/Volume Stats

Current price $1.58 52-week high $1.95
Prev. close $1.54 52-week low $0.66
Day low $1.53 Volume 30,600
Day high $1.61 Avg. volume 83,239
50-day MA $1.51 Dividend yield N/A
200-day MA $1.21 Market Cap 45.69M

CADL Stock Price Chart Interactive Chart >


Candel Therapeutics, Inc. (CADL) Company Bio


Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.


CADL Latest News Stream


Event/Time News Detail
Loading, please wait...

CADL Latest Social Stream


Loading social stream, please wait...

View Full CADL Social Stream

Latest CADL News From Around the Web

Below are the latest news stories about CANDEL THERAPEUTICS INC that investors may wish to consider to help them evaluate CADL as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!

William White on InvestorPlace | December 18, 2023

Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.

Yahoo | December 13, 2023

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PD

Yahoo | December 12, 2023

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409

Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024Prioritizes development of CAN-3110 in recurrent high-grade glioma and initiation of investigational new drug (IND)-enabling studies in second indicationPlans to broaden discovery partnership opportunities based on the enLIGHTEN™ Discovery PlatformExtends cash run

Yahoo | November 28, 2023

Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress

Advancements in Viral Immunotherapy Trials and Financial Health

Yahoo | November 9, 2023

Read More 'CADL' Stories Here

CADL Price Returns

1-mo -11.73%
3-mo 7.48%
6-mo 71.74%
1-year 14.29%
3-year N/A
5-year N/A
YTD 7.48%
2023 -17.88%
2022 -77.11%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!